0001123292-18-000997.txt : 20181003
0001123292-18-000997.hdr.sgml : 20181003
20181003184218
ACCESSION NUMBER: 0001123292-18-000997
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181001
FILED AS OF DATE: 20181003
DATE AS OF CHANGE: 20181003
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shaw Allan
CENTRAL INDEX KEY: 0001626850
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33389
FILM NUMBER: 181106493
MAIL ADDRESS:
STREET 1: C/O CELSUS THERAPEUTICS PLC
STREET 2: 24 WEST 40TH STREET
CITY: NEW YORK
STATE: NY
ZIP: 10018
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VIVUS INC
CENTRAL INDEX KEY: 0000881524
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943136179
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 E. HAMILTON AVENUE
STREET 2: SUITE 550
CITY: CAMPBELL
STATE: CA
ZIP: 95008
BUSINESS PHONE: 6509345200
MAIL ADDRESS:
STREET 1: 900 E. HAMILTON AVENUE
STREET 2: SUITE 550
CITY: CAMPBELL
STATE: CA
ZIP: 95008
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-10-01
0000881524
VIVUS INC
VVUS
0001626850
Shaw Allan
C/O VIVUS, INC.
900 E. HAMILTON AVE., SUITE 550
CAMPBELL
CA
95008
1
0
0
0
Common Stock
2018-10-01
4
M
0
139
A
6432
D
Common Stock
2018-10-01
4
F
0
43
5.63
D
6389
D
On September 10, 2018, VIVUS, Inc. effected a 1-for-10 reverse stock split (the "Reverse Split"). Accordingly, 1,389 shares of common stock on a pre-Reverse Split basis were adjusted to 139 shares following the Reverse Split (with fractional shares rounded up to the next whole number). The shares of common stock relate to the previously disclosed restricted stock units that vested on September 15, 2018 and released on October 1, 2018.
Restricted stock units converted into VIVUS, Inc. common stock on a 1-for-1 basis upon vesting.
The number of shares beneficially owned following the reported transaction has been adjusted to reflect the Reverse Split (with fractional shares rounded up to the next whole number).
The reporting person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than by way of forfeiture to VIVUS, Inc. in order to cover estimated tax liability.
The price reported for the securities is the market value on the business day immediately before September 15, 2018.
/s/ Julie Hollenback, Attorney-in-Fact
2018-10-03